Uppsala 2022-09-19 Emplicure AB (publ) announces today that the Company's Board of Directors has resolved to implement a holding company structure with operational subsidiaries. The purpose of the restructuring is to increase visibility and reinforce the Group's ability to focus on business and product development across various product areas, including nicotine and pharmaceuticals as well as other consumer product areas. As a direct consequence of the above, the Board of Directors has appointed Tomas Hammargren as CEO of the subsidiary Amplicon.

Uppsala 2022-09-19 Emplicure AB (publ) announces today that the Company's Board of Directors has resolved to appoint member of the board and co-founder Håkan Engqvist as new CEO and President. 

The UK authorities have approved Emplicure's application to conduct a clinical pharmacokinetic study of Empli03, a drug candidate for chronic pain.

There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches.

Amplicon, a wholly owned subsidiary of Emplicure AB that focuses on developing consumer products, successfully showcased two dry white nicotine-pouch products at the Global Forum on Nicotine in Warsaw on 16-18 June 2022.

Emplicure's CEO Torbjörn Walker Larsson presented the company at Aktiespararnas Småbolagsdagar in Stockholm yesterday. If you could not participate or missed the event, click on the link below to watch the presentation in streaming mode.

Amplicon, a wholly owned subsidiary of Emplicure AB (publ), that focuses on developing consumer products, today announced that it has filed at the European Union Intellectual Property Office (EUIPO) for a trademark registration for its leading product.

Emplicure AB (publ) ("Emplicure" or the "Company") announces the outcome of the exercise of warrants of series TO1, which were issued during the second quarter of 2021. A total of 5,902,512 warrants of series TO1 were exercised, corresponding to approximately 61.5 percent of outstanding warrants of series TO1, for subscription of 5,902,512 shares at a subscription price of SEK 2.09 per share. Through the exercise of the warrants of series TO1, Emplicure receives approximately SEK 12.3 million before issue costs.

Johan Wieslander, who is a board member of Emplicure AB (publ) ("Emplicure" or the "Company"), has acquired an additional 1,500,000 warrants of series TO1, in addition to the warrants previously held by him that have already been exercised for subscription of shares in the Company. Johan Wieslander  has exercised the the additional 1,500,000 warrants for subscription of 1,500,000 shares in the Company, meaning that the Company receives approximately SEK 3.1 million.

Today, May 11 2022, is the last day for trading with warrants of series TO1 in Emplicure AB (publ) ("Emplicure" or the "Company"). The subscription period runs up to and including May 13 2022. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.09 per share.